

## SUPPLEMENTAL TABLE 1

# FDA-APPROVED THERAPEUTICS FOR CANCER RISK REDUCTION OR TREATMENT OF PRECANCEROUS CONDITIONS\*

### Cancer Risk Reduction

| Condition   | Generic Name  | Trade Name         |
|---|---|--------------------|
| Breast cancer   | raloxifene<br>tamoxifen   | Evista<br>Nolvadex |
| Cervical, vulvar, vaginal, and anal cancers and dysplasia; genital warts                | human papillomavirus quadrivalent vaccine (Types 6, 11, 16, and 18)                 | Gardasil           |
| Cervical, head and neck, vulvar, vaginal, and anal cancers and dysplasia; genital warts | human papillomavirus 9-valent vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) | Gardasil 9         |
| Cervical cancer and cervical dysplasia  | human papillomavirus bivalent vaccine (Types 16 and 18)                             | Cervarix           |

### Treatment of Precancerous Conditions

| Condition            | Generic Name  | Trade Name                               |
|----------------------|---|--|
| Actinic keratosis    | ingenol mebutate<br>fluorouracil<br>diclofenac sodium<br>5-aminolevulinic acid + photodynamic therapy (PDT)<br>masoprocol/nordihydroguaiaretic acid | Picato<br>Adricil<br>Voltaren<br>Actinex |
| Bladder dysplasia    | bacillus Calmette-Guerin (BCG)<br>valrubicin  | Valstar                                  |
| Esophageal dysplasia | porfimer sodium + photodynamic therapy (PDT)  | Photofrin                                |

\*Adapted from Wu X, Patterson S, Hawk E. *Chemoprevention* – History and general principles. Best Practice Research Clinical Gastroenterology. 2011;25:445-59.